[Ip-health] Xtandi 2016 March-In Request
claire.cassedy at keionline.org
Thu Jan 14 10:14:04 PST 2016
Xtandi 2016 March-In Request
Submitted by James Love on 13. January 2016 - 17:45
Today Knowledge Ecology International and the Union for Affordable Cancer
Treatment (UACT) petitioned the Department of Health and Human Services,
the Department of Defense, and the National Institutes of Health, asking
that they exercise federal "march-in" rights to end the monopoly on an
expensive prostate cancer drug, enzalutamide, marketed as Xtandi by
Astellas, a Japanese pharmaceutical company.
Xtandi was invented at UCLA on federal grants from the NIH and DoD.
The basis of the March-in request is that the price of Xtandi is 2 to 4
times higher in the U.S. than in other high income countries, and that the
"march-in" provisions in the Bayh-Dole Act should be used to protect U.S.
consumers from excessive prices.
The average wholesale price (AWP) for Xtandi is $88.48 per capsule in the
U.S., more than three times the price Astellas charges in Japan and more
than four times the price in Canada.
Below this blog post is a link to a pdf of the request, and of the press
Ed Silverman, "Taxpayer money helped create this cancer drug. Should we be
able to force the price down? ," Pharmalot, Stat News, Boston Globe,
Jan. 14, 2016.
Carolyn Y. Johnson, "Taxpayers helped fund this $129,000 cancer drug.
Should the government help cut the price? ," Washington Post, Jan. 14,
Emily Wasserman, "NIH and HHS get 'march-in' request for Astellas' Xtandi
," FiercePharma, Jan. 14, 2016.
More information about the Ip-health